{
    "clinical_study": {
        "@rank": "24869", 
        "arm_group": [
            {
                "arm_group_label": "HMS 90\u00ae", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo (Soy protein)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blind, placebo-controlled, Phase IV trial , comparing HMS 90\u00ae versus\n      placebo (soy protein) as add-on (adjuvant) therapy in subjects with idiopathic Parkinson's\n      Disease.\n\n      The principal objective is to evaluate the changes in biomarkers of oxidative stress\n      and,plasma amino acids, as well as improvement of clinical symptoms and brain function"
        }, 
        "brief_title": "Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90\u00ae) in Patients With Parkinson's Disease", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Parkinson Disease", 
            "Parkinsonian Disorders", 
            "Basal Ganglia Diseases", 
            "Brain Diseases", 
            "Central Nervous System Diseases", 
            "Nervous System Diseases", 
            "Movement Disorders", 
            "Neurodegenerative Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Basal Ganglia Diseases", 
                "Brain Diseases", 
                "Central Nervous System Diseases", 
                "Ganglion Cysts", 
                "Movement Disorders", 
                "Nervous System Diseases", 
                "Parkinson Disease", 
                "Parkinsonian Disorders", 
                "Neurodegenerative Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects with Idiopathic Parkinson's Disease\n\n          2. Subjects who are willing and able to participate in the trial and has provided\n             written, informed consent.\n\n        Exclusion Criteria:\n\n          1. Subjects  who are allergic to Whey protein (HMS 90\u00ae).\n\n          2. Subjects who are treated  with chemotherapy .\n\n          3. Subjects with any history of neurodegenerative diseases,  e.g., Alzheimer's disease.\n\n          4. Subjects with history of diabetes. 4.5. Subjects with abnormal liver function test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662414", 
            "org_study_id": "53653"
        }, 
        "intervention": [
            {
                "arm_group_label": "HMS 90\u00ae", 
                "description": "1 sachect (10 g) 2times/ day", 
                "intervention_name": "Whey protein", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo (Soy protein)", 
                "description": "1 sachect (10g) 2times/day", 
                "intervention_name": "Soy protein", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pathumwan", 
                    "country": "Thailand", 
                    "state": "Bangkok", 
                    "zip": "10330"
                }, 
                "name": "Chulalongkorn University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90\u00ae) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function", 
        "overall_official": {
            "affiliation": "Chulalongkorn University", 
            "last_name": "Roongroj Bhidayasiri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Biomarkers of oxidative stress, i.e., plasma glutathione (reduced and oxidized forms), urinary 8-hydroxydeoxyguanosine, and urinary total antioxidant status", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Concentrationsrofiles of plasma amino acids and their derivatives  Brain function by PET-Scan", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662414"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Unified Parkinson's Disease Rating Scale (UPDRS) Section III (motor) score change from baseline to week 24", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Unified Parkinson's Disease Rating Scale (UPDRS) Section II (ADL) score change baseline to week 24", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "\u2022 Clinical Global impression (CGI) - Change scale score, change from baseline to week 24", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "\u2022 Clinical Global impression (CGI) - Severity scale score change from baseline to week 24", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "\u2022 Parkinson's Disease quality of life questionnaire score change from baseline to week 24", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Nutrition Questionnaire score change baseline to week 24", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}